Evaluation of Intralipid efficacy for decreasing Amphotericin B-related nephrotoxicity

Phase 2

• Conditions: Condition 1: Fungal Infections. Condition 2: Fungal Infections. Condition 3: Fungal Infections.; Aspergillosis; Zygomycosis; Unspecified mycosis

• Registration Number: IRCT2012110411364N1
• Lead Sponsor: Vice chancellor for research, Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

patients with fungal infections admitted in Amir-Alam and Imam Khomeini hospitals in Tehran during 1390-1391 who need Amphotericin B for treatment.

Exclusion criteria: pathologic hyperlipidemia; patient receiving other nephrotoxic drugs like aminoglycoside simultaneously; severe liver failure or cirrhosis; ESRD under hemodialysis or peritoneal dialysis; baseline serum creatinine over 2mg/dL; hypersensitivity to fat emulsions,egg and soya; pancreatitis

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum creatinie level. Timepoint: baseline and daily during intervention. Method of measurement: milligram per deciliter (mg/dL) with blood sampling.

Secondary Outcome Measures

Name	Time	Method
Serum potassium level. Timepoint: baseline and daily during intervention. Method of measurement: milliequivalent per liter (mEq/L) with blood sampling.